Niagen Bioscience (NAGE) Raw Materials (2018 - 2019)
Niagen Bioscience (NAGE) posted quarterly Raw Materials of $1.4 million for Q4 2019, down 39.49% year-over-year from $2.3 million in Q4 2018, and down 39.49% quarter-over-quarter from $2.3 million in Q4 2018.
Niagen Bioscience (NAGE) Raw Materials (2018 - 2019) Analysis & Trends
Niagen Bioscience (NAGE) has reported Raw Materials for 2 consecutive years, with $1.4 million the latest figure, recorded in Q4 2019.
- In Q4 2019, Raw Materials fell 39.49% year-over-year to $1.4 million; the TTM figure through Dec 2019 stood at $1.4 million (down 39.49% YoY), while the FY2019 annual figure was $1.4 million, down 39.49% from the prior year.
- Raw Materials slipped to $1.4 million in Q4 2019 per NAGE's latest filing, from $2.3 million in the prior quarter.
- Across five years, Raw Materials topped out at $2.3 million in Q4 2018 and bottomed at $1.4 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Niagen Bioscience | 238.30 Mn | 171.56 Mn | 19.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 1.36 Mn |
| Dec 31, 2018 | 2.25 Mn |